Advertisement

Journal of Neuro-Oncology

, Volume 126, Issue 2, pp 355–360 | Cite as

Development of brain metastases in patients with metastatic melanoma while receiving ipilimumab

  • C. Frenard
  • L. Peuvrel
  • M. Saint Jean
  • A. Brocard
  • A. C. Knol
  • J. M. Nguyen
  • A. Khammari
  • G. Quereux
  • B. Dreno
Clinical Study

Abstract

Ipilimumab is a monoclonal antibody blocking the inhibitory molecule CTLA4 expressed by activated T lympocytes, used for the treatment of metastatic melanoma. Recent studies have shown its potential efficacy on brain metastases. Objectives: To assess the development of brain metastases under ipilimumab and identify clinical, histological or evolving criteria related to the appearance of these metastases. A retrospective study was conducted in 52 patients treated with 4 cycles of ipilimumab 3 mg/kg every 3 weeks for unresectable stage III or stage IV melanoma between January 2011 and July 2013 in a Department of Dermato-Oncology. As no data has been find in the literature, the results were compared to our other cohort of patients treated with vemurafenib during the same period. Ten patients (21.7 %) developed brain metastases under ipilimumab in a median time of 6.58 months after treatment initiation. The multivariate analysis showed a lower rate of brain metastases in patients with acral lentiginous melanoma and melanoma of unknown primary site. The median survival after diagnosis of brain metastases was of 2.5 months. There was no significant difference with vemurafenib-treated patients in terms of incidence rate of brain metastasis, time of development and survival after diagnosis of cerebral metastases. This was the first study focused on the development of brain metastases under treatment with ipilimumab 3 mg/kg. Although ipilimumab is used for the treatment of brain metastases, it paradoxically did not seem to reduce the risk of developing brain metastases.

Keywords

Melanoma Brain metastases Ipilimumab 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Erdmann F, Lortet-Tieulent J, Schüz J, Zeeb H, Greinert R, Breitbart EW, Bray F (2013) International trends in the incidence of malignant melanoma 1953–2008—are recent generations at higher or lower risk? Int J Cancer 132:385–400PubMedCrossRefGoogle Scholar
  2. 2.
    Patchell RA (2003) The management of brain metastases. Cancer Treat Rev 29:533–540PubMedCrossRefGoogle Scholar
  3. 3.
    Davies MA, Liu P, McIntyre S, Kim KB, Papadopoulos N, Hwu W-J, Hwu P, Bedikian A (2011) Prognostic factors for survival in melanoma patients with brain metastases. Cancer 117:1687–1696PubMedCrossRefGoogle Scholar
  4. 4.
    Patel JK, Didolkar MS, Pickren JW, Moore RH (1978) Metastatic pattern of malignant melanoma. A study of 216 autopsy cases. Am J Surg 135:807–810PubMedCrossRefGoogle Scholar
  5. 5.
    Hofmann M, Kiecker F, Wurm R, Schlenger L, Budach V, Sterry W, Trefzer U (2006) Temozolomide with or without radiotherapy in melanoma with unresectable brain metastases. J Neurooncol 76:59–64PubMedCrossRefGoogle Scholar
  6. 6.
    Kim G, McKee AE, Ning Y-M et al (2014) FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAF V600E mutation. Clin Cancer Res Off J Am Assoc Cancer Res. doi: 10.1158/1078-0432.CCR-14-0776 Google Scholar
  7. 7.
    Graziani G, Tentori L, Navarra P (2012) Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer. Pharmacol Res 65:9–22PubMedCrossRefGoogle Scholar
  8. 8.
    Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Queirolo P, Spagnolo F, Ascierto PA et al (2014) Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases. J Neurooncol. doi: 10.1007/s11060-014-1400-y PubMedPubMedCentralGoogle Scholar
  10. 10.
    Di Giacomo AM, Ascierto PA, Pilla L et al (2012) Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol 13:879–886PubMedCrossRefGoogle Scholar
  11. 11.
    Knisely JPS, Yu JB, Flanigan J, Sznol M, Kluger HM, Chiang VLS (2012) Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg 117:227–233PubMedCrossRefGoogle Scholar
  12. 12.
    Silk AW, Bassetti MF, West BT, Tsien CI, Lao CD (2013) Ipilimumab and radiation therapy for melanoma brain metastases. Cancer Med 2:899–906PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Prins RM, Vo DD, Khan-Farooqi H, Yang M-Y, Soto H, Economou JS, Liau LM, Ribas A (2006) NK and CD4 cells collaborate to protect against melanoma tumor formation in the brain. J Immunol 177:8448–8455PubMedCrossRefGoogle Scholar
  14. 14.
    Takeshima T, Chamoto K, Wakita D, Ohkuri T, Togashi Y, Shirato H, Kitamura H, Nishimura T (2010) Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: its potentiation by combination with Th1 cell therapy. Cancer Res 70:2697–2706PubMedCrossRefGoogle Scholar
  15. 15.
    Hamilton R, Krauze M, Romkes M et al (2013) Pathologic and gene expression features of metastatic melanomas to the brain. Cancer 119:2737–2746PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Cao Y, Tsien CI, Shen Z, Tatro DS, Ten Haken R, Kessler ML, Chenevert TL, Lawrence TS (2005) Use of magnetic resonance imaging to assess blood-brain/blood-glioma barrier opening during conformal radiotherapy. J Clin Oncol Off J Am Soc Clin Oncol 23:4127–4136CrossRefGoogle Scholar
  17. 17.
    Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE (2004) Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the metropolitan Detroit cancer surveillance system. J Clin Oncol 22:2865–2872PubMedCrossRefGoogle Scholar
  18. 18.
    Schouten LJ, Rutten J, Huveneers HAM, Twijnstra A (2002) Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 94:2698–2705PubMedCrossRefGoogle Scholar
  19. 19.
    Amer MH, Al-Sarraf M, Baker LH, Vaitkevicius VK (1978) Malignant melanoma and central nervous system metastases. Incidence, diagnosis, treatment and survival. Cancer 42:660–668PubMedCrossRefGoogle Scholar
  20. 20.
    Sampson JH, Carter JH Jr, Friedman AH, Seigler HF (1998) Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg 88:11–20PubMedCrossRefGoogle Scholar
  21. 21.
    Raizer JJ, Hwu W-J, Panageas KS et al (2008) Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features. Neuro-Oncol 10:199–207PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Bedikian AY, Wei C, Detry M, Kim KB, Papadopoulos NE, Hwu W-J, Homsi J, Davies M, McIntyre S, Hwu P (2011) Predictive factors for the development of brain metastasis in advanced unresectable metastatic melanoma. Am J Clin Oncol 34:603–610PubMedCrossRefGoogle Scholar
  23. 23.
    Schoenewolf NL, Belloni B, Simcock M, Tonolla S, Vogt P, Scherrer E, Holzmann D, Dummer R (2014) Clinical implications of distinct metastasizing preferences of different melanoma subtypes. Eur J Dermatol EJD. doi: 10.1684/ejd.2014.2292 PubMedGoogle Scholar
  24. 24.
    Gumusay O, Coskun U, Akman T et al (2014) Predictive factors for the development of brain metastases in patients with malignant melanoma: a study by the Anatolian society of medical oncology. J Cancer Res Clin Oncol 140:151–157PubMedCrossRefGoogle Scholar
  25. 25.
    Papadatos-Pastos D, Soultati A, Harries M (2013) Targeting brain metastases in patients with melanoma. BioMed Res Int 2013:1–6CrossRefGoogle Scholar
  26. 26.
    Posner JB, Chernik NL (1978) Intracranial metastases from systemic cancer. Adv Neurol 19:579–592PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • C. Frenard
    • 1
  • L. Peuvrel
    • 1
  • M. Saint Jean
    • 1
  • A. Brocard
    • 1
  • A. C. Knol
    • 1
  • J. M. Nguyen
    • 1
  • A. Khammari
    • 1
  • G. Quereux
    • 1
  • B. Dreno
    • 1
  1. 1.Department of dermatologySkin Cancer Unit, Nantes University Hospital, INSERM 892Nantes Cedex 1France

Personalised recommendations